

Paola Imbriani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8795611/publications.pdf>

Version: 2024-02-01

30
papers

629
citations

567144

15
h-index

610775

24
g-index

32
all docs

32
docs citations

32
times ranked

1029
citing authors

#	ARTICLE	IF	CITATIONS
1	Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. <i>Frontiers in Neurology</i> , 2019, 10, 148.	1.1	89
2	Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum. <i>ELife</i> , 2018, 7, .	2.8	60
3	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. <i>Sleep Medicine</i> , 2016, 21, 140-144.	0.8	55
4	Centrality of Early Synaptopathy in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 103.	1.1	41
5	A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus. <i>Frontiers in Neurology</i> , 2015, 6, 86.	1.1	39
6	Abnormal striatal plasticity in a DYT11/SGCE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition. <i>Neurobiology of Disease</i> , 2017, 108, 128-139.	2.1	34
7	Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus. <i>Journal of Neural Transmission</i> , 2018, 125, 673-679.	1.4	31
8	Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart. <i>PLoS ONE</i> , 2014, 9, e101763.	1.1	26
9	Association between physical activity and dementia's risk factors in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2019, 126, 319-325.	1.4	26
10	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	1.4	25
11	Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia. <i>Neurobiology of Disease</i> , 2020, 134, 104634.	2.1	22
12	Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3407.	1.8	18
13	A Dual Centre Study of Pain in Parkinson's Disease and Its Relationship with Other Non-Motor Symptoms. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1817-1825.	1.5	17
14	Assessment of serum uric acid as risk factor for tauopathies. <i>Journal of Neural Transmission</i> , 2017, 124, 1105-1108.	1.4	16
15	Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 57-63.	1.1	16
16	Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1-deficient mice. <i>Synapse</i> , 2016, 70, 223-230.	0.6	14
17	Heidenhain variant in two patients with inherited V210I Creutzfeldt-Jakob disease. <i>International Journal of Neuroscience</i> , 2016, 126, 381-3.	0.8	14
18	Dystonia: Are animal models relevant in therapeutics?. <i>Revue Neurologique</i> , 2018, 174, 608-614.	0.6	11

#	ARTICLE	IF	CITATIONS
19	Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinson's disease. <i>Neurological Sciences</i> , 2013, 34, 383-386.	0.9	10
20	Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings. <i>Clinical Neurology and Neurosurgery</i> , 2017, 156, 63-65.	0.6	10
21	The influence of postural deformities on neck function and pain in patients with Parkinson's disease. <i>NeuroRehabilitation</i> , 2019, 44, 79-84.	0.5	10
22	Vesicular Acetylcholine Transporter Alters Cholinergic Tone and Synaptic Plasticity in <sc>DYT1</sc> Dystonia. <i>Movement Disorders</i> , 2021, 36, 2768-2779.	2.2	10
23	Promising rodent models in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 46, S10-S14.	1.1	9
24	Alpha-Synuclein is Involved in <sc>DYT1</sc> Dystonia Striatal Synaptic Dysfunction. <i>Movement Disorders</i> , 2022, 37, 949-961.	2.2	7
25	Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Possible Detection of Overlaps with Frailty Process. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 538-546.	0.8	5
26	Synaptic effects of ethanol on striatal circuitry: therapeutic implications for dystonia. <i>FEBS Journal</i> , 2022, 289, 5834-5849.	2.2	4
27	Outlining a Population at Risk of Parkinson's Disease: Evidence from a Case-Control Study. <i>Parkinson's Disease</i> , 2016, 2016, 1-7.	0.6	3
28	Long-term treatment with rotigotine in drug-naïve PSP patients. <i>Acta Neurologica Belgica</i> , 2019, 119, 113-116.	0.5	3
29	Occurrence of Writing Tremor in Patients With Scans Without Evidence of Dopaminergic Deficit. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 421-424.	0.8	2
30	«Crisi d'ansia reattiva»: un caso particolare di infortunio sul lavoro. <i>Pratica Medica & Aspetti Legali</i> , 2012, 5, 119-121.	0.0	0